在艾美赛珠单抗存在下准确评估艾夫凝血因子α的凝血因子Ⅷ活性
本研究为多中心方法学评估,7个中心用牛源发色底物法分别以标准校准品和艾夫凝血因子α特异性校准品检测含艾夫凝血因子α(有/无艾美赛珠单抗)的血浆样本。结果显示标准校准品严重高估凝血因子Ⅷ活性,而艾夫凝血因子α特异性校准可准确测定,且不受艾美赛珠单抗干扰。
要点
- 标准校准品校准的发色底物法严重高估艾夫凝血因子α的凝血因子Ⅷ活性。
- 艾夫凝血因子α特异性校准可准确测定凝血因子Ⅷ活性,室内及室间变异低。
- 艾美赛珠单抗对艾夫凝血因子α特异性校准的发色底物法测定无干扰。
核心结论
- 使用艾夫凝血因子α和牛源试剂对凝血因子Ⅷ发色底物法进行特异性校准,可准确测定接受艾夫凝血因子α治疗患者的凝血因子Ⅷ活性,即使在艾美赛珠单抗存在下。
研究设计与样本
- 方法学评估研究,5个国家7个中心接收12份血浆样本,每份样本在3个独立日以2种校准方法各检测3次。
- 样本包括仅含艾夫凝血因子α(凝血因子Ⅷ活性5至150 IU/dL)的6份样本,以及艾夫凝血因子α(凝血因子Ⅷ活性5至150 IU/dL)联合艾美赛珠单抗(50 μg/mL)的5份样本。
- 另1份样本含艾夫凝血因子α(凝血因子Ⅷ活性50 IU/dL)和高剂量艾美赛珠单抗(80 μg/mL),还有1份样本含艾夫凝血因子α(凝血因子Ⅷ活性50 IU/dL)和低剂量艾美赛珠单抗(20 μg/mL)。
- 各中心使用自己的分析仪及常规试剂。
主要发现
- 以标准校准品校准的发色底物法严重高估凝血因子Ⅷ活性。
- 以艾夫凝血因子α特异性校准可准确测定凝血因子Ⅷ活性,室内和室间变异低,且无艾美赛珠单抗干扰。
- 研究中使用的所有发色底物法试剂在不同实验室间变异低,室间变异系数范围为9%至20%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efanesoctocog is a B-domain-deleted, Fc-fusion factor (F)VIII linked to the D'D3 domain of von Willebrand factor and 2 XTEN polypeptides, designed for an ultra-extended half-life for prophylaxis in hemophilia A, but also aiding in managing acute bleeding or surgery in patients on long-term emicizumab. However, no current laboratory method accurately measures FVIII levels in the presence of emicizumab. OBJECTIVES: To test whether the bovine chromogenic FVIII assay, specifically calibrated for efanesoctocog, could provide an accurate assessment of efanesoctocog activity. METHODS: Seven centers across 5 countries received 12 plasma samples to measure in triplicate using 2 calibration methods across 3 independent days. Samples (n = 6) contained either only efanesoctocog (FVIII activity [FVIII:C]= 5 to 150 IU/dL), or efanesoctocog (FVIII:C = 5 to 150 IU/dL) in combination with emicizumab (50 μg/mL; n = 5). One sample contained efanesoctocog (FVIII:C = 50 IU/dL) and a high dose of emicizumab (80 μg/mL); another sample contained efanesoctocog (FVIII:C = 50 IU/dL) with a low dose of emicizumab (20 μg/mL). Each center used its own analyzers, along with their usual reagents. RESULTS: Chromogenic assay (CSA) calibrated with standard calibrators highly overestimates FVIII:C. However, specific calibration with efanesoctocog enabled accurate measurement of FVIII:C, with low inter- and intra-laboratory variability, and no interference from emicizumab. All CSA reagents used in the study demonstrated low variability across different laboratories (interlaboratory coefficient of variation ranges between 9% and 20%). CONCLUSION: Specific calibration of the FVIII CSA using efanesoctocog and bovine reagents allows for accurate measurement of FVIII:C in patients receiving efanesoctocog, even in the presence of emicizumab.
引用
- Nougier C, Pipe SW, Pabinger I, et al. Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab. J Thromb Haemost. 2025. PMID: 39798924. doi:10.1016/j.jtha.2024.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。